A Long-term Open-label Study of DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension -Phase 3-

NCT01343082 Phase 3 COMPLETED Results posted

Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.

Details

Lead sponsor	Santen Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	COMPLETED
Enrolment	148
Start date	2011-05

Conditions

• Open Angle Glaucoma or Ocular Hypertension

Interventions

• DE-111 ophthalmic solution

Primary outcomes

• Change From Baseline in IOP (Intraocular Pressure) at End of Study — Treatment period: Week 0 (Baseline) and Week 52 (End of Study)

Countries

Japan